Interestingly, tumors with mutations in exon 11 of c-Kit's juxtamembrane region are particularly sensitive to imatinib, whereas those with exon 9 mutations (extracellular domain) respond better to sunitinib than imatinib. In the future, primary therapy for GIST may be determined by the specific molecular defect in c-Kit.
Ref: Harrison's Principles of Internal Medicine, 18th Edition
It seems this is something very new. No one even told us in coaching.
ReplyDelete